drugset / Trial / NCT00814021

Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain

NCT00814021 ↗

Phase 2 Completed 21 enrolled Institut Claudius Regaud
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with kidney cancer that has spread to the brain.

Timeline

Start
2009-04
Primary completion
2010-12
Completion
2011-03

Outcome

Missed primary endpoint

paper However, no BM showed an OR. PMID 24268852 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunitinib Small molecule — Oral